- 著者
-
Kentaro Iwata
Wataru Igarashi
Midori Honjo
Takashi Nishimoto
Kyoko Shinya
Akiko Makino
Kazuo Mitani
Yoshiko Tatsumi
Hiroyuki Ninomiya
Kumi Higasa
Seiichiro Usuki
Hiroki Kagawa
Daisuke Uchida
Kohei Takimoto
Rei Suganaga
Hiroo Matsuo
Yuichiro Oba
Mami Horigome
Hideaki Oka
Goh Ohji
Yasuhisa Abe
Hiroyuki Yoshida
Shohiro Kinoshita
Midori Hirai
- 出版者
- 日本プライマリ・ケア連合学会
- 雑誌
- General Medicine (ISSN:13460072)
- 巻号頁・発行日
- vol.14, no.1, pp.13-22, 2013 (Released:2013-07-05)
- 参考文献数
- 34
- 被引用文献数
-
3
Background: Gingyo-gedoku-san (GGGS) is an herbal medicine approved for upper respiratory infections in Japan. We conducted an open-label, multi-center, prospective trial, comparing GGGS with oseltamivir in patients with influenza and influenza-like illness (ILI) as a pilot study.Methods: Subjects were healthy persons aged between 16 and 40, and were enrolled from January 12, 2010 to March 24, 2011. Fifteen patients were enrolled in this trial (8 and 7 for GGGS and oseltamivir, respectively). RT-PCR was positive for pandemic influenza A (H1N1) in 10 patients. The patients were provided with either GGGS or oseltamivir for 5 days. The primary outcome was mortality and/or hospitalization 7 days after the initial diagnosis. Body temperature and other clinical characteristics were also evaluated.Results: All patients recovered from illness without complication or hospitalization. The mean time to resolve symptoms for the GGGS and oseltamivir groups was 3.9 days and 3.3 days, respectively (p=0.43). The GGGS group appeared to have a smaller symptom score AUC than the oseltamivir group, (p=0.26). Time to recover activity level appeared to be shorter in the GGGS group (p=0.10), with shorter time to recover health status (p=0.02). Sub-group analysis on patients with positive PCR showed similar results between the two groups.Conclusion: GGGS was associated with symptom improvements resembling oseltamivir for both influenza and ILI. Randomized controlled trials involving larger sample sizes are needed to confirm these results.